BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control.
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 405
- Registration Number
- NCT00750113
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Phase 1
Completed
- Conditions
- Prostate CancerPharmacokineticsMetastases
- Interventions
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00748046
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Completed
- Conditions
- FibrosisKidney FailureRenal Insufficiency
- Interventions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 168
- Registration Number
- NCT00744939
Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome
Phase 4
Completed
- Conditions
- Metabolic SyndromeErectile Dysfunction
- Interventions
- Drug: Vardenafil (Levitra, BAY38-9456)Drug: Placebo
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT00738400
Inhibition of Ovulation, Patch, Ethinylestradiol and Gestodene
Phase 2
Terminated
- Conditions
- ContraceptionOvulation Inhibition
- Interventions
- Drug: Ethinylestradiol/Gestodene (BAY86-5016)
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17
- Registration Number
- NCT00729404
Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 312
- Registration Number
- NCT00720057
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia
Phase 3
Completed
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT00717561
Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients
Phase 3
Withdrawn
- Conditions
- HypertensionDiabetic Nephropathies
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Bayer
- Registration Number
- NCT00713011
Nebido Versus Placebo in Elderly Men With Typical Symptoms of Late Onset Hypogonadism Over a Period of 54 Weeks
Phase 4
Withdrawn
- Conditions
- Hypogonadism
- Interventions
- Drug: NEBIDODrug: PLACEBO
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Bayer
- Registration Number
- NCT00710827
Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging
Phase 3
Completed
- Conditions
- Diagnostic ImagingCentral Nervous System Diseases
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 402
- Registration Number
- NCT00709852
- Locations
- 🇮🇳
Piramal Diagnostic- Jankharia Imaging, Mumbai, Maharashtra, India
🇩🇪Universitätsklinikum Erlangen, Erlangen, Bayern, Germany
🇩🇪LMU Klinikum der Universität München - Großhadern, München, Bayern, Germany
© Copyright 2025. All Rights Reserved by MedPath